{"id":"W3175514092","doi":"10.1016/j.jtocrr.2021.100205","title":"Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston General Hospital","funders":"Janssen Pharmaceuticals; Loxo Oncology; Chugai Pharmaceutical; Genentech; Free Market Institute, Texas Tech University; National Institutes of Health; Shire; Bayer Fund; Mirati Therapeutics; Clovis Oncology; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Verily Life Sciences; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; AbbVie; ACEA Biosciences; Novartis; Celgene; Merck; Spectrum Pharmaceuticals; Sanofi; EMD Serono; Mesothelioma Applied Research Foundation; Heron Therapeutics; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Pfizer; Boehringer Ingelheim; Amgen; Roche","keywords":"Pembrolizumab; Medicine; Brain metastasis; Internal medicine; Chemotherapy; Lung cancer; Oncology; Confidence interval; Metastasis; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002472147,0.0002372442,0.00114834,0.0003963906,0.0001015009,0.00006716058,0.00005597814,0.0001448376,0.00004666193],"category_scores_gemma":[0.0004376344,0.0001253115,0.0001482267,0.001413446,0.0008425505,0.0001018669,0.00006004687,0.0004716675,2.241656e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005356997,"about_ca_system_score_gemma":0.000550615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009730728,"about_ca_topic_score_gemma":0.001559943,"domain_scores_codex":[0.9963225,0.0004227197,0.0008840775,0.0007367835,0.001195198,0.0004387341],"domain_scores_gemma":[0.9972173,0.0007883341,0.0002811687,0.0005100145,0.0009107706,0.0002924024],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03086979,0.001608516,0.9356974,0.00008571864,0.005846528,0.001744086,0.0002413518,0.000001986853,0.0001020312,0.000009075253,0.00007167624,0.0237218],"study_design_scores_gemma":[0.0165473,0.004926771,0.9755144,0.0003249765,0.0009413733,0.00009374024,0.0002551239,0.00003249603,0.0004888466,0.00002819999,0.0006617074,0.0001850243],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958009,0.0008509588,0.00003146217,0.002062477,0.00001984898,0.001009598,0.00002749614,0.00001616606,0.0001811636],"genre_scores_gemma":[0.9977393,0.0003807587,0.0006620489,0.0003649329,0.00001978196,0.00006323052,0.0001265181,0.00002833074,0.0006151093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03981699,"threshold_uncertainty_score":0.5110055,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04276317074613412,"score_gpt":0.4012464907436726,"score_spread":0.3584833199975385,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}